Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Assembly Biosciences ( (ASMB) ) has provided an announcement.
On May 22, 2026, Assembly Biosciences announced that it will expand clinical development of its oral NTCP inhibitor candidate ABI-6250, originally aimed at chronic hepatitis delta virus infection, into primary biliary cholangitis and primary sclerosing cholangitis, extending the program across cholestatic liver diseases. The move, supported by preclinical, pharmacologic and Phase 1a data as well as a recent pre-IND discussion with the U.S. Food and Drug Administration, positions the company to initiate a Phase 2 HDV trial in the fourth quarter of 2026 and a Phase 2 basket study in cholestatic liver diseases in the first quarter of 2027, targeting substantial unmet need in PBC non-responders and PSC patients who currently lack approved therapies.
PBC and PSC are chronic autoimmune cholestatic liver diseases marked by impaired bile flow, bile acid buildup and progressive liver damage, for which current treatment options are limited or nonexistent. By blocking the sodium taurocholate co-transporting polypeptide, ABI-6250 aims to modulate bile acid transport and HDV entry, offering a mechanistically distinct oral therapy that could differentiate Assembly Biosciences in the competitive liver disease space if later-stage trials confirm safety and efficacy.
The most recent analyst rating on (ASMB) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Assembly Biosciences stock, see the ASMB Stock Forecast page.
Spark’s Take on ASMB Stock
According to Spark, TipRanks’ AI Analyst, ASMB is a Neutral.
The score is held back primarily by weak cash flow and ongoing unprofitability despite a strong, low-leverage balance sheet. Technicals are moderately positive with the stock above key moving averages, while valuation is constrained by losses (negative P/E) and no dividend yield data. A modestly positive corporate governance/compensation update provides limited incremental support.
To see Spark’s full report on ASMB stock, click here.
More about Assembly Biosciences
Assembly Biosciences, Inc. is a biotechnology company focused on developing innovative small-molecule therapeutics for serious viral and liver diseases, including herpesviruses, hepatitis delta virus (HDV), cholestatic liver diseases and hepatitis B virus. The company aims to change disease trajectories and improve outcomes for patients with chronic, hard-to-treat conditions worldwide.
Average Trading Volume: 104,733
Technical Sentiment Signal: Sell
Current Market Cap: $417.3M
See more data about ASMB stock on TipRanks’ Stock Analysis page.